Literature DB >> 18609163

Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study.

Mårten Werner1, Hanne Prytz, Bodil Ohlsson, Sven Almer, Einar Björnsson, Annika Bergquist, Sven Wallerstedt, Hanna Sandberg-Gertzén, Rolf Hultcrantz, Per Sangfelt, Ola Weiland, Ake Danielsson.   

Abstract

OBJECTIVE: Autoimmune hepatitis (AIH) is a chronic liver disease, which if untreated can lead to cirrhosis and hepatic failure. The aim of the study was to investigate the incidence, prevalence, diagnostic tradition and clinical initial presentation of AIH.
MATERIAL AND METHODS: Analyses were performed in 473 patients identified as having probable or definite AIH.
RESULTS: The incidence of AIH was 0.85/100,000 (95% CI 0.69-1.01) inhabitants, which is somewhat lower than reported previously. The point prevalence amounted to 10.7/100,000 (95% CI 8.8-13.1), and 76% of the cases were females. The age-related incidence curve was bimodal but men were found to have only one incidence peak in the late teens, whereas women had a peak after menopause. AIH was presented as a spectrum of clinical settings from detected "en passant" to acute liver failure. Almost 30% of patients already had liver cirrhosis at diagnosis. Autoantibodies indicative of AIH type 1 were found in 79% of cases. Other concomitant autoimmune diseases were frequently found (49%).
CONCLUSIONS: The incidence and prevalence figures confirm that AIH is a fairly uncommon disease in the Swedish population. Symptoms at presentation were unspecific, but almost half of the patients were jaundiced, with around 30% having liver cirrhosis. The majority of Swedish AIH patients had AIH type 1.

Entities:  

Mesh:

Year:  2008        PMID: 18609163     DOI: 10.1080/00365520802130183

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  48 in total

1.  Autoimmune Hepatitis in Hawai'i.

Authors:  Tanner I Kim; Jaclyn E Kagihara; Naoky C S Tsai; Marina M Roytman
Journal:  Hawaii J Med Public Health       Date:  2015-08

2.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

Review 3.  Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2017-07-14       Impact factor: 3.199

Review 4.  Current concepts in the diagnosis and management of autoimmune hepatitis.

Authors:  Stephen Kriese; Michael A Heneghan
Journal:  Frontline Gastroenterol       Date:  2012-11-12

Review 5.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Authors:  Andrew M Moon; Amit G Singal; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-08       Impact factor: 11.382

Review 6.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

Review 7.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 8.  Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases.

Authors:  Glinda S Cooper; Milele L K Bynum; Emily C Somers
Journal:  J Autoimmun       Date:  2009-10-09       Impact factor: 7.094

9.  Race/ethnicity is an independent risk factor for autoimmune hepatitis among the San Francisco underserved.

Authors:  Briton Lee; Edward W Holt; Robert J Wong; Justin L Sewell; Ma Somsouk; Mandana Khalili; Jacquelyn J Maher; Michele M Tana
Journal:  Autoimmunity       Date:  2018-06-11       Impact factor: 2.815

Review 10.  Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.